Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 50

Results For "TD"

1174 News Found

Glenmark Pharma reports Q2 FY24 loss at Rs. 62 Cr
News | November 13, 2023

Glenmark Pharma reports Q2 FY24 loss at Rs. 62 Cr

European operations' revenue grew 58.4% to Rs 599.7 crore


Marksans Pharma posts Q2 FY24 consolidated PAT at Rs. 82.7 Cr
News | November 13, 2023

Marksans Pharma posts Q2 FY24 consolidated PAT at Rs. 82.7 Cr

US business grew by +12.8% YoY


SMS Pharmaceuticals reports robust Q2FY24 operational performance
News | November 10, 2023

SMS Pharmaceuticals reports robust Q2FY24 operational performance

Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore


GSK registers 5% revenue growth in Q2 FY24
News | November 10, 2023

GSK registers 5% revenue growth in Q2 FY24

General Medicine grows 5% and Vaccines 10% led by Shingrix


Bayer posts Q3 2023 Group sales Euro 10.34 billion
News | November 09, 2023

Bayer posts Q3 2023 Group sales Euro 10.34 billion

We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”


Biocon Biologics announces divestment of two non-core branded formulations
News | November 09, 2023

Biocon Biologics announces divestment of two non-core branded formulations

Total transaction value of the divestment is Rs. 3,660 million


Zydus, Guardant Health to promote Guardant360 genomic tests for cancers in India and Nepal
Healthcare | November 04, 2023

Zydus, Guardant Health to promote Guardant360 genomic tests for cancers in India and Nepal

The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region


Tatva Chintan Pharma Chem reports Q2 FY24 consolidated PAT at Rs. 7.78 Cr
News | November 04, 2023

Tatva Chintan Pharma Chem reports Q2 FY24 consolidated PAT at Rs. 7.78 Cr

Tatva Chintan Pharma Chem has reported total income of Rs. 97.42 crores during the period ended September 30, 2023


Dr Lal Path Labs posts Q2 FY24 consolidated PAT at Rs. 109.3 Cr
News | November 03, 2023

Dr Lal Path Labs posts Q2 FY24 consolidated PAT at Rs. 109.3 Cr

Dr. Lal Path Labs has reported total income of Rs. 619.4 crores during the period ended September 30, 2023